Mei Meng

1.3k total citations
51 papers, 824 citations indexed

About

Mei Meng is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Mei Meng has authored 51 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 16 papers in Immunology and 10 papers in Cancer Research. Recurrent topics in Mei Meng's work include Immune Response and Inflammation (7 papers), Immunotherapy and Immune Responses (4 papers) and Intensive Care Unit Cognitive Disorders (3 papers). Mei Meng is often cited by papers focused on Immune Response and Inflammation (7 papers), Immunotherapy and Immune Responses (4 papers) and Intensive Care Unit Cognitive Disorders (3 papers). Mei Meng collaborates with scholars based in China, United States and Poland. Mei Meng's co-authors include Quansheng Zhou, Craig M. Coopersmith, Nathan J. Klingensmith, Ping Yang, Zhifei Cao, Jing Zhao, Jianchang Chen, Yanyan Pan, Zhe Zhao and Chengyong Qin and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Cancer Research.

In The Last Decade

Mei Meng

51 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mei Meng China 18 397 140 121 115 108 51 824
Xuguang Hu China 15 379 1.0× 90 0.6× 107 0.9× 163 1.4× 78 0.7× 48 814
Xiaowen Yu China 19 440 1.1× 119 0.8× 128 1.1× 139 1.2× 119 1.1× 46 1.1k
Simiao Qiao China 16 434 1.1× 172 1.2× 83 0.7× 102 0.9× 88 0.8× 32 865
Xiaoling Wang China 18 407 1.0× 112 0.8× 88 0.7× 72 0.6× 126 1.2× 42 883
Hui Lin China 22 642 1.6× 113 0.8× 139 1.1× 179 1.6× 154 1.4× 73 1.4k
Hassan Mehrad‐Majd Iran 15 230 0.6× 95 0.7× 118 1.0× 109 0.9× 127 1.2× 86 798
Xia Zhong China 19 423 1.1× 163 1.2× 56 0.5× 122 1.1× 198 1.8× 42 1.1k
Bihao Liu China 21 377 0.9× 105 0.8× 47 0.4× 96 0.8× 125 1.2× 24 830
Yun‐Ho Kim South Korea 19 310 0.8× 124 0.9× 79 0.7× 47 0.4× 83 0.8× 46 910
Qi He China 17 280 0.7× 104 0.7× 60 0.5× 91 0.8× 94 0.9× 61 730

Countries citing papers authored by Mei Meng

Since Specialization
Citations

This map shows the geographic impact of Mei Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei Meng more than expected).

Fields of papers citing papers by Mei Meng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei Meng. The network helps show where Mei Meng may publish in the future.

Co-authorship network of co-authors of Mei Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Mei Meng. A scholar is included among the top collaborators of Mei Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei Meng. Mei Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
He, Jian, Nianxiang Qiu, Mei Meng, et al.. (2023). Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies. Frontiers in Oncology. 12. 1007653–1007653. 8 indexed citations
3.
Meng, Mei, Juntao Liu, Xiaoxiao Song, et al.. (2023). Lycorine inhibits pancreatic cancer cell growth and neovascularization by inducing Notch1 degradation and downregulating key vasculogenic genes. Biochemical Pharmacology. 217. 115833–115833. 6 indexed citations
4.
Meng, Mei, Rui Gao, Fengxiang Liu, et al.. (2023). Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients. Frontiers in Pharmacology. 14. 1085509–1085509. 7 indexed citations
5.
Klingensmith, Nathan J., Katherine Fay, John D. Lyons, et al.. (2022). Junctional adhesion molecule-A deletion increases phagocytosis and improves survival in a murine model of sepsis. JCI Insight. 7(16). 16 indexed citations
6.
Meng, Mei, Shi‐Jian Ding, Kaiyan Feng, et al.. (2022). Identification of COVID-19 severity biomarkers based on feature selection on single-cell RNA-Seq data of CD8+ T cells. Frontiers in Genetics. 13. 1053772–1053772. 5 indexed citations
7.
Zhang, Mengli, Mei Meng, Yuxi Liu, et al.. (2021). Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins. Breast Cancer Research. 23(1). 21 indexed citations
8.
He, Jian, Rui Gao, Mei Meng, et al.. (2021). Lysophosphatidic Acid Receptor 6 (LPAR6) Is a Potential Biomarker Associated with Lung Adenocarcinoma. International Journal of Environmental Research and Public Health. 18(21). 11038–11038. 7 indexed citations
9.
Yang, Ping, Mei Meng, & Quansheng Zhou. (2021). Oncogenic cancer/testis antigens are a hallmarker of cancer and a sensible target for cancer immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1876(1). 188558–188558. 29 indexed citations
10.
Zhao, Zhe, Mengli Zhang, Jun Yao, et al.. (2020). Correction of the tumor suppressor Salvador homolog-1 deficiency in tumors by lycorine as a new strategy in lung cancer therapy. Cell Death and Disease. 11(5). 387–387. 17 indexed citations
12.
Meng, Mei, Zhenyu Tian, Jingjing Wang, et al.. (2018). Pharmacological preconditioning with the cellular stress inducer thapsigargin protects against experimental sepsis. Pharmacological Research. 141. 114–122. 10 indexed citations
14.
Zheng, Nana, Bin Zhang, Mei Meng, et al.. (2016). Thrombomodulin reduces tumorigenic and metastatic potential of lung cancer cells by up-regulation of E-cadherin and down-regulation of N-cadherin expression. Biochemical and Biophysical Research Communications. 476(4). 252–259. 18 indexed citations
15.
Pan, Yanyan, Mei Meng, Nana Zheng, et al.. (2016). Targeting of multiple senescence-promoting genes and signaling pathways by triptonide induces complete senescence of acute myeloid leukemia cells. Biochemical Pharmacology. 126. 34–50. 33 indexed citations
17.
Chen, Jianchang, et al.. (2014). Etanercept Attenuates Myocardial Ischemia/Reperfusion Injury by Decreasing Inflammation and Oxidative Stress. PLoS ONE. 9(9). e108024–e108024. 79 indexed citations
18.
Wang, Jing, Shulei Zhao, Yan Li, Mei Meng, & Chengyong Qin. (2012). 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Induces Retinoic Acid Receptor β Hypermethylation through DNA Methyltransferase 1 Accumulation in Esophageal Squamous Epithelial Cells. Asian Pacific Journal of Cancer Prevention. 13(5). 2207–2212. 18 indexed citations
19.
Chu, Yufeng, Mei Meng, Juan Zeng, et al.. (2012). Effectiveness of Combining Plasma Exchange With Continuous Hemodiafiltration on Acute Fatty Liver of Pregnancy Complicated by Multiple Organ Dysfunction. Artificial Organs. 36(6). 530–534. 18 indexed citations
20.
Zhang, Yijing, Ming Li, Mei Meng, Mei Feng, & Chengyong Qin. (2009). The effect of ulinastation on the small intestine injury and mast cell degranulation in a rat model of sepsis induced by CLP. Experimental and Toxicologic Pathology. 61(5). 481–490. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026